Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-1.38 Insider Own1.80% Shs Outstand195.89M Perf Week2.30%
Market Cap609.22M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float192.37M Perf Month13.09%
Income-268.50M PEG- EPS next Q-0.24 Inst Own67.30% Short Float27.40% Perf Quarter88.48%
Sales25.10M P/S24.27 EPS this Y-3.80% Inst Trans0.07% Short Ratio13.39 Perf Half Y100.65%
Book/sh-0.59 P/B- EPS next Y15.10% ROA-65.10% Target Price2.50 Perf Year-6.33%
Cash/sh0.80 P/C3.89 EPS next 5Y- ROE- 52W Range1.26 - 4.55 Perf YTD115.97%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-90.80% 52W High-31.65% Beta2.70
Dividend %- Quick Ratio1.00 Sales past 5Y-30.20% Gross Margin92.00% 52W Low146.83% ATR0.16
Employees227 Current Ratio1.00 Sales Q/Q72.10% Oper. Margin- RSI (14)62.32 Volatility4.75% 5.63%
OptionableYes Debt/Eq- EPS Q/Q21.10% Profit Margin- Rel Volume0.44 Prev Close3.10
ShortableYes LT Debt/Eq- EarningsApr 30 AMC Payout- Avg Volume3.94M Price3.11
Recom2.60 SMA2010.23% SMA5014.52% SMA20029.85% Volume1,719,492 Change0.32%
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-06-08Reiterated Lazard Capital Buy $12 → $10
Aug-06-08Downgrade Canaccord Adams Buy → Hold
Jul-08-08Initiated Canaccord Adams Buy $7.30
Dec-07-07Reiterated Fortis Bank Hold $10 → $9
Sep-14-07Initiated Lazard Capital Buy $14
Apr-17-15 11:57AM  3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog
Apr-16-15 10:30AM  Exelexis (EXEL) Is The 'Chart of the Day' at TheStreet
Apr-13-15 08:14AM  Bulls can't get enough of Exelixis
Apr-10-15 04:49PM  Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog
Apr-09-15 05:38PM  Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 at noodls +5.61%
05:05PM  Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Business Wire
02:32PM  Exelixis (EXEL) Stock Rises Today Following FDA Fast Track Designation at TheStreet
09:17AM  Exelixis Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma at noodls
08:30AM  Exelixis Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma Business Wire
Apr-01-15 06:00AM  Roche open to alliances in hunt for cancer drug combinations Reuters
Mar-30-15 07:16PM  Cramer Remix: In all my years, never seen this! at CNBC +6.30%
05:13PM  3 (Rough) Dates Exelixis Shareholders Need to Know at Investopedia
Mar-25-15 05:00PM  Biotech in nice uptrend: Adami -6.20%
Mar-18-15 08:45AM  Is Exelixis (EXEL) Stock a Solid Choice Right Now? - Tale of the Tape
Mar-11-15 05:33PM  GSK's big bet: Tapping our body's electronics at CNBC
12:04PM  18 Biotech Stocks These Wall Street Analysts Are Tracking
Mar-10-15 01:04PM  EXELIXIS, INC. Financials
Mar-09-15 04:11PM  EXELIXIS, INC. Files SEC form 8-K, Other Events
Mar-06-15 09:42PM  Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3 at noodls
09:42PM  Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update at noodls
06:00PM  Is Exelixis Under-the-Radar Growth? at Investopedia
Mar-02-15 05:17PM  EXELIXIS, INC. Files SEC form 10-K, Annual Report +5.46%
Feb-27-15 09:29AM  Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape
Feb-26-15 04:05PM  Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3 Business Wire +8.92%
Feb-24-15 07:12PM  Exelixis reports 4Q loss AP
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:10PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:06PM  Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q4 2014 Exelixis Inc Earnings Release - After Market Close CCBN
Feb-23-15 02:30PM  Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Zacks
Feb-19-15 09:03AM  Ahead of the Bell: Exelixis shares climb, FDA to review drug AP
01:00AM  Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Feb-11-15 05:16PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:51AM  Exelixis (EXEL) Catches Eye: Stock Adds 15.9% in Session - Tale of the Tape Zacks
Feb-10-15 02:01PM  4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More at TheStreet +15.87%
Feb-05-15 03:37PM  Exelixis Data Release Upcoming; Options Activity Spiking Benzinga
Feb-02-15 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015 Business Wire
Jan-29-15 04:10PM  Exelixis to Present at the Leerink Global Healthcare Conference on Wednesday, February 11 Business Wire
Jan-07-15 08:30AM  Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer Business Wire
Dec-31-14 08:59AM  19 Lesser-Known Biotech Stocks With Robust Drug Pipelines Benzinga +6.67%
Dec-15-14 01:00AM  Exelixis Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Dec-05-14 05:16PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
Dec-02-14 01:29PM  Exelixis Shares Down on COMET-2 Study Results on Cabozantinib Zacks
Dec-01-14 11:37AM  Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study at TheStreet -10.24%
10:23AM  Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol Benzinga
08:00AM  Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer Business Wire
Nov-25-14 04:05PM  Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Business Wire
Nov-16-14 04:20AM  Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib Business Wire
Nov-11-14 04:40PM  Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Business Wire
Nov-06-14 06:00AM  Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma Business Wire
Nov-04-14 07:21PM  Exelixis tops 3Q profit forecasts AP
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:16PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:14PM  Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer Business Wire
04:13PM  Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update Business Wire
04:02PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q3 2014 Exelixis Inc Earnings Release - After Market Close CCBN
Nov-03-14 01:35PM  Will Exelixis (EXEL) Disappoint This Earnings Season? Zacks
Oct-16-14 05:16PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Oct-15-14 04:10PM  EXELIXIS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Stateme EDGAR Online
Oct-14-14 04:12PM  Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014 Business Wire
Oct-03-14 08:50AM  Roche Presents Data on Cancer Immunotherapy Candidate Zacks
08:42AM  Exelixis (EXEL) Is in Oversold Territory: What's Next? Zacks
Sep-29-14 11:14AM  Cancer drug stocks on the move amid striking data at CNBC
09:19AM  Ahead of the Bell: Exelixis shares soar AP
03:00AM  Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Sep-25-14 05:22PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Sep-18-14 06:43AM  Why Exelixis (EXEL) Stock Might be a Great Pick Zacks
Sep-17-14 01:00AM  Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress Business Wire
Sep-08-14 04:05PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9 Business Wire
Sep-05-14 05:23PM  EXELIXIS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities EDGAR Online
08:55AM  Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte at TheStreet
Sep-04-14 08:06AM  Piramal, Exelixis And Novo Nordisk Research Woes Spell Doom For Drug Discovery Scientists at Forbes
Sep-03-14 06:14PM  Most active Nasdaq-traded stocks AP
09:40AM  Exelixis Slumps 55% on Disappointing Cabozantinib Results Zacks
08:40AM  Exelixis (EXEL) Enters Oversold Territory Zacks
Sep-02-14 12:25PM  Exelixis Plunges On Drug Trial Failure; Investors See Potential StockTwits -55.31%
10:40AM  S&P 500 flat after ISM data; Staples, Regeneron pop at MarketWatch
10:40AM  After the Exelixis Implosion, Is There Anything Left Ahead? at 24/7 Wall St.
10:21AM  Apple, Tesla hit intraday records; Conns falls at MarketWatch
10:01AM  Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today at TheStreet
09:33AM  Exelixis Drug Fails Pivotal Prostate Cancer Study at TheStreet
09:24AM  Fight for Family Dollar heats up; Tesla powers ahead; Exelixis tanks Hot Stock Minute
09:10AM  Ahead of the Bell: Exelixis shares tumble AP
08:54AM  US STOCKS-Wall St set for flat open; manufacturing data on tap Reuters
08:20AM  Story Stocks from Briefing.com Briefing.com
08:14AM  Exelixis downgraded by Stifel Briefing.com
07:41AM  US STOCKS-Futures inch higher ahead of manufacturing data Reuters
Sep-01-14 07:02PM  Exelixis to cut jobs after prostate cancer drug fails late-stage study Reuters
06:00PM  Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer Business Wire
Aug-06-14 06:00AM  The R&D elite: America's most innovative companies at CNBC
Aug-01-14 09:45AM  Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today at TheStreet
Jul-31-14 05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN -5.62%
04:17PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:13PM  Exelixis Announces Second Quarter 2014 Financial Results Business Wire
04:03PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q2 2014 Exelixis, Inc. Earnings Release - After Market Close CCBN
Jul-25-14 09:50AM  Exelixis (EXEL) In A Perilous Reversal at TheStreet
06:34AM  Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session Zacks
Jul-22-14 05:02PM  Is this Exelixis Stock's Worst Nightmare? at Motley Fool
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.003,125078,730Nov 18 06:57 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.002,083037,237Nov 18 06:55 PM
BURKE DEBORAHSVP & Chief Financial OfficerNov 15Option Exercise0.006,438019,377Nov 18 06:52 PM
MARCHESI VINCENT TDirectorSep 17Buy1.7120,00034,19945,000Sep 19 05:05 PM